Inactive Instrument

Novoheart Holdings Inc. Stock

Equities

NVH

CA67011V1076

Biotechnology & Medical Research

Dynamic Chart
Novoheart Holdings Inc.(TSXV:NVH) dropped from S&P/TSX Venture Composite Index CI
Novomed Limited completed the acquisition of 12.6% stake in Novoheart Holdings Inc.. CI
Novomed Limited entered into a definitive arrangement agreement to acquire 12.6% stake in Novoheart Holdings Inc. for CAD 12.6 million. CI
Novoheart Holdings Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020 CI
Novoheart Holdings Inc. Announces Directorship Appointments CI
Novoheart Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 CI
Novoheart Holdings Inc. Announces Change of its Fiscal Year-End to December 31, from June 30 CI
Novoheart Announces the Completion of a Research and Development Contract Sponsored by a Top 10 Global Pharma CI
Novoheart Announces an Exclusive Licensing Agreement with Harvard University's Office of Technology Development CI
Novoheart Announces Change of Fiscal Year-End CI
Novoheart Holdings Inc. Announces Management Changes CI
Novoheart to Co-develop First of its Kind Human Heart-in-a-Jar Model of Heart Failure with AstraZeneca CI
Novoheart Holdings Inc. Reports Earnings Results for the First Quarter Ended September 30, 2019 CI
Novoheart Holdings Inc. Demonstrates Advanced Capabilities for Drug Screening as Well as Disease Modeling Which Can Lead to Safer Drugs with Better Efficacy, According to New Research CI
Novoheart Holdings Inc. Reports Earnings Results for the Full Year Ended June 30, 2019 CI
More news
Novoheart Holdings Inc is a Canada-based holding company. The Company, through its subsidiary, provides, discovers and develops heart therapeutics. Novoheart's scientific team has pioneered a range of bioengineering technologies collectively known as the MyHeart platform, including first human mini-heart “novoHeart” that is capable of fully capable of pumping and ejecting fluid. It is currently partnering with a pharmaceutical company to develop human heart tissues and chambers that carry a hereditary neurodegenerative disease. It is anticipated that the pharmaceutical company will be able to use the developed pathological tissues as a unique drug discovery and drug screening platform for effective therapies targeting the heart-associated issues of this specific disease. Novoheart is currently completing the build out a large commercial laboratory in Asia to enable it to service additional potential commercial partnerships, which are under discussion.
More about the company